ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2026
Multi-omics identification of amino acid and redox dysregulation in cystic fibrosis-related diabetes.
Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCystic fibrosis-related diabetes (CFRD) is one of the most common extrapulmonary complications of cystic fibrosis (CF), characterized by abnormal glucose tolerance due primarily to insulin insufficiency. CF-related prediabetes (CFRpD) represents an asymptomatic stage before CFRD onset, requiring routine screening for detection. We aimed to characterize the metabolic profiles underlying abnormal glucose tolerance in people living with CF (pwCF) and identify disrupted pathways associated with CFRD progression.
methodsFasting plasma samples from pwCF with normal glucose tolerance (CF-NGT), CFRpD, CFRD, and from healthy, normoglycemic controls without CF were analyzed using liquid chromatography-mass spectrometry (LC-MS)-based metabolomics and lipidomics. Annotated metabolites were used for their individual profiles and pathway analysis.
resultsPlasma BCAAs, choline, and methionine were lower in CFRD compared to CF-NGT, and leucine, isoleucine, and methionine were also lower in CFRpD after adjusting for sex and CFTR modulator use. In addition, LPCs and the percentage of methionine oxidation (%OxMet) were significantly higher in CFRD. Lean mass and LMI correlated positively with BCAAs and methionine, though only valine was significant after adjusting for sex in pwCF. In agreement with individual metabolites, pathway analysis indicated disruptions in BCAA biosynthesis and one-carbon metabolism in CFRD.
conclusionThese findings suggest that impairments in branchedchain amino acid metabolism, redox balance, and one-carbon metabolism are associated with the pathogenesis of CFRD, including lower lean mass in the case of valine. These metabolites should be further tested as potential biomarkers of CF(p)RD and may provide mechanistic insights into CFRD pathogenesis and therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.